Zobrazeno 1 - 10 of 10 pro vyhledávání: '"P M, Mulani"'
1
Akademický článek
Gastric schwannoma: a benign tumor often misdiagnosed as gastrointestinal stromal tumor
Autor: Apurva S. Shah, Pravin M. Rathi, Vaibhav S. Somani, Astha M. Mulani
Publikováno v: Clinics and Practice, Vol 5, Iss 3 (2015)
Gastric schwannomas are rare mesenchymal tumors that arise from the nerve plexus of gut wall. They present with nonspecific symptoms and are often detected incidentally. Preoperative investigation is not pathognomic and many are therefore misdiagnose
Externí odkaz: https://doaj.org/article/0070d32a26c9465892e0115d583b5ae3
Zobrazit plný text záznamu
2
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study
Autor: C, Leonardi, J M, Sobell, J J, Crowley, U, Mrowietz, Y, Bao, P M, Mulani, Y, Gu, M M, Okun
Publikováno v: The British journal of dermatology. 167(3)
The clinical utility of increasing to weekly adalimumab therapy in patients with psoriasis with inadequate response to every other week (eow) dosing is unknown.(i) To determine the effectiveness of escalating adalimumab dosage from 40 mg eow to 40 mg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9ad373bcf812125a9299eca93a3b09cc
https://pubmed.ncbi.nlm.nih.gov/22928715
Zobrazit plný text záznamu
3
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy
Autor: S, Lichtiger, D G, Binion, D C, Wolf, D H, Present, A G, Bensimon, E, Wu, A P, Yu, A T, Cardoso, J, Chao, P M, Mulani, K G, Lomax, J D, Kent
Publikováno v: Alimentary pharmacologytherapeutics. 32(10)
Adalimumab induces and maintains remission in adults with Crohn's disease.To evaluate safety, fistula healing, quality of life and work productivity in adalimumab-treated patients who failed infliximab, including primary nonresponders.After a ≥8-we
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7db4605410b27fc7511624a9562fddcd
https://pubmed.ncbi.nlm.nih.gov/20955442
Zobrazit plný text záznamu
4
Economic burden of comorbidities in patients with psoriasis is substantial
Autor: A B, Kimball, A, Guérin, M, Tsaneva, A P, Yu, E Q, Wu, S R, Gupta, Y, Bao, P M, Mulani
Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV. 25(2)
Psoriasis is frequently associated with comorbidities.To estimate the incremental economic burden associated with comorbidities in patients with psoriasis, accounting for psoriasis severity.Patients continuously enrolled ≥6 months after a randomly
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5ba0460c2eb1b69d2134e7d17a60f166
https://pubmed.ncbi.nlm.nih.gov/20561129
Zobrazit plný text záznamu
5
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
Autor: R, Panaccione, J-F, Colombel, W J, Sandborn, P, Rutgeerts, G R, D'Haens, A M, Robinson, J, Chao, P M, Mulani, P F, Pollack
Publikováno v: Alimentary pharmacologytherapeutics. 31(12)
In the randomized, double-blind, placebo-controlled CHARM trial, adalimumab was more effective than placebo in maintaining clinical remission for patients with moderate-to-severe Crohn's disease (CD) through 56 weeks.To substantiate the long-term saf
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ff1579849f4e80d7624946798bfc2166
https://pubmed.ncbi.nlm.nih.gov/20298496
Zobrazit plný text záznamu
6
Systematic review: the costs of ulcerative colitis in Western countries
Autor: R D, Cohen, A P, Yu, E Q, Wu, J, Xie, P M, Mulani, J, Chao
Publikováno v: Alimentary pharmacologytherapeutics. 31(7)
Early onset and complications such as hospitalization and surgery contribute to the economic burden of ulcerative colitis.To review systematically the literature on costs of ulcerative colitis in Western countries.Studies estimating costs of ulcerati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::945f1b17e338b3ec10c5d4619e341b71
https://pubmed.ncbi.nlm.nih.gov/20064142
Zobrazit plný text záznamu
7
Racial differences in use of biologics for crohn's disease in a medicaid population
Autor: P M Mulani, M Yang, M Lu, J Chao, Raymond K. Cross, Mark Flasar
Publikováno v: Gut. 60:A138-A138
Introduction Immunomodulator (IMM) and biologic (anti-TNF) use in African Americans (AA) with Crohn9s disease (CD) has been reported to be lower than in white patients (W); few data exist for Hispanic patients (H). We assessed racial differences in i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a5cf0b042ebcda18b66ec976226a4ef
https://doi.org/10.1136/gut.2011.239301.292
Zobrazit plný text záznamu
9
Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease
Autor: M Yang, R B Thakkar, Z Li, P M Mulani, P F Pollack, Edward V. Loftus, J Chao
Publikováno v: Gut. 60:A137-A137
Introduction No randomised clinical trials have compared early treatment with anti-TNF agents and conventional delayed step-up treatment for patients with moderate to severe Crohn9s disease (CD). The goal of this study was to project remission rates
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a809995b8ffa190d3413e83664bdb346
https://doi.org/10.1136/gut.2011.239301.291
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje